1. Scrip
  2. >>Business
  3. >>Deals

Boehringer Buys Abexxa To Boost Cancer Pipeline

Provided Initial Funding For Start-Up In 2016

 
• By Kevin Grogan

The latest in a series of deals that Boehringer Ingelheim has inked in the oncology space will see the German family-run firm acquire US biotech Abexxa.

Boehringer Ingelheim headquarters in Ingelheim, Germany
(dieth+schröder-fotografie)

More than five years after providing seed funding for Abexxa Biologics Inc, Boehringer Ingelheim GmbHhas decided to acquire the US-based oncology start-up which is developing what the German group hopes will be "the next generation of precision medicines designed to revolutionize cancer treatments."

Abexxa, a spin-out from the University of Texas at Arlington, specializes in targeting cancer-specific proteins that are located inside the cell, rather than those expressed on the cell membrane. This...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By Joseph Haas

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

More from Business

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By Kevin Grogan

Buy boosts the French major's immunology pipeline.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.